Rainbow Childrens Medicare
Mainboard₹1,581 Cr issue
-6.64%
Listing gain over issue price
Issue size
₹1,581 Cr
1 lot at cut-off
₹14,634
Lot size
27shares
Open
27 Apr 2022
Close
29 Apr 2022
Allotment
05 May 2022
Listing
10 May 2022
Listing performance
Issue price
₹542
Listed at
₹506
Listing-day close
₹450.20
Latest price
₹1,169.60
Close on 23 Oct 2026
Listing gain
-6.64%
Return since issue
+115.79%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 27 Apr 2022 – 29 Apr 2022
- Listing date
- 10 May 2022
- Face value
- ₹10 per share
- Issue price
- ₹542 per share
- Lot size
- 27 shares
- Total issue size
- ₹1,581 Cr
- Market cap at offer price
- ₹5,501 Cr
- Promoter holding
- 62.19% → 49.83% pre-issue → post-issue
- ISIN
- INE961O01016
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- Kotak Mahindra Capital Co.Ltd.
- Registered office
- 8-2-120/103/1, Survey No.403, Banjara Hills, Telangana
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 86,63,404 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 27 shares per lot, in multiples, at ₹542
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 27 | ₹14,634 |
| Retail (max) | 13 | 351 | ₹1,90,242 |
| S-HNI (min) | 14 | 378 | ₹2,04,876 |
| S-HNI (max) | 68 | 1,836 | ₹9,95,112 |
| B-HNI (min) | 69 | 1,863 | ₹10,09,746 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
86,63,404
Anchor portion
₹470 Cr
at ₹542 per share
Valuation and performance
Valuation at offer price
₹542 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 4.36 | — |
| P/E (×) | 124.31 | — |
| Market cap | — | ₹5,501 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 8.88%
- ROCE
- 10.48%
- Debt / equity
- 0.11
- PAT margin
- 6.10%
- NAV per share
- ₹48.82
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Rainbow Childrens Medicare
Rainbow Children's Medicare Limited is a leading multi-specialty pediatric and obstetrics and gynecology hospital chain in India. As of December 31, 2021, the company operated 14 hospitals and 3 clinics across six cities with a total bed capacity of 1,500 beds. The company's core specialties are pediatrics (including newborn and pediatric intensive care, pediatric multi-specialty services, and pediatric quaternary care including multi-organ transplants) and obstetrics and gynecology (including normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility care). The company generates revenue through hospital operations, professional services rendered by medical professionals, and pharmacy sales.
Company Analysis
from RHPRainbow Children's Medicare Limited is a leading multi-specialty pediatric and obstetrics and gynecology hospital chain operating across India's healthcare sector.
Rainbow Children's Medicare Limited is a leading multi-specialty pediatric and obstetrics and gynecology hospital chain in India. As of December 31, 2021, the company operated 14 hospitals and 3 clinics across six cities with a total bed capacity of 1,500 beds. The company's core specialties are pediatrics (including newborn and pediatric intensive care, pediatric multi-specialty services, and pediatric quaternary care including multi-organ transplants) and obstetrics and gynecology (including normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility care). The company generates revenue through hospital operations, professional services rendered by medical professionals, and pharmacy sales.
Healthcare servicesHospital operationsPediatric healthcareObstetrics and gynecologyFertility services
Objects of the Issue
- Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, one of our Group Companies, in full ₹400.00 million p.26
- Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals ₹1,700.00 million p.26
- General Corporate Purposes ₹562.00 million p.26
- Setting up of new hospitals and purchase of medical equipment for such new hospitals ₹1,700 million p.64
- General corporate purposes p.64
- Early redemption of Non-Convertible Debentures issued by our Company to CDC Emerging Markets Limited in full ₹400.00 million p.159
- Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals ₹1,700.00 million p.159
- General corporate purposes ₹562.00 million p.159
- Funding capex for setting up and equipping new hospitals and expanding existing healthcare facilities p.299
- General corporate purposes
Issue Structure
- Total Issue
- ₹15,808.49 million
- Fresh Issue
- ₹2,800.00 million (5,177,121 Equity Shares)
- Offer for Sale
- ₹13,008.49 million (24,000,900 Equity Shares)
- Price Band
- ₹516 to ₹542 per Equity Share
- Lot Size
- 27 Equity Shares and in multiples of 27 Equity Shares thereafter
- Face Value
- ₹10 per Equity Share
Business Model
The company operates a hospital chain specializing in pediatric and women's healthcare services. Revenue is generated through inpatient and outpatient services provided at its hospitals and clinics. The company engages doctors primarily on a consultancy service contract basis and employs nurses and paramedical staff. The company also operates a pharmacy business within its hospitals.
Business Segments
Provides newborn and pediatric intensive care, pediatric multi-specialty services, and pediatric quaternary care including multi-organ transplants
Provides normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility care
Provision of comprehensive outpatient and inpatient tertiary and quaternary care through hub hospitals and secondary care in pediatric, obstetrics and gynecology and emergency services through spoke facilities
Provides comprehensive pediatric healthcare services including newborn and pediatric intensive care, pediatric multi-specialty services (neurology, nephrology, gastroenterology, oncology, cardiology), and pediatric quaternary care including multi-organ transplants. Services span secondary, tertiary and quaternary care with advanced critical care programs.
Provides comprehensive perinatal care under the 'Birthright by Rainbow' brand, including normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic care, and fertility treatment services (IUI, IVF, ICSI, IMSI). Services include high-risk pregnancy care, neonatal care, gynecological services, and assisted reproductive technology.
Rainbow Children's Hospital provides comprehensive pediatric medical services including general pediatrics, pediatric gastroenterology, hepatology, nutrition, and other pediatric specialties
BirthRight by Rainbow provides obstetrics, gynecology, and fertility services including IVF treatments and related reproductive healthcare
Rainbow Speciality Hospitals operates multi-specialty hospital services providing general and specialized medical treatments across multiple disciplines
Rosewalk Healthcare provides inpatient, outpatient and home care services through establishing and operating hospitals, specialty centers, day care centers, OPD clinics, and diagnostic centers
Provides inpatient and outpatient hospital services including accommodation, surgery, medical/clinical professional services, food and beverages, investigation and supply of pharmaceutical and related products
Sale of pharmacy and pharmaceutical items
Medical service fees recognized when related services are rendered
Provides inpatient and outpatient healthcare services including obstetrics, neonatology, pediatrics and other specialty services
Retail and wholesale distribution of pharmaceuticals and medical supplies to patients and other healthcare providers
SWOT Analysis
Strengths
- • Leading multi-specialty pediatric and obstetrics hospital chain with significant bed capacity(p.25)
- • Specialized expertise in core pediatric and obstetric specialties including quaternary care(p.25)
- • Demonstrated financial performance with positive net worth and profitability(p.28)
- • Hub-and-spoke model with established reputation enabling referrals(p.64)
- • Strong brand recognition with registered trademarks across multiple languages(p.68)
- • Investment in new hospitals and medical equipment funded by net proceeds(p.64)
- • Credit rating of AA- stable from ICRA(p.69)
- • Established regional presence in pediatric and maternity care(p.209)
- • Proven hub-and-spoke model with synergies and referral networks(p.163)
- • Positioned in high-growth pediatric and maternity care segments(p.211)
- • Multi-specialty capabilities in pediatric and perinatal care(p.176)
- • Experienced senior management and institutional shareholder support(p.176)
- • Largest pediatric multi-specialty hospital chain by bed capacity among peers(p.247)
- • Specialized children's hospital model with integrated perinatal care(p.248)
- • Full-time doctor engagement model ensuring 24/7 availability(p.245)
- • Proven hub-and-spoke model generating synergies and patient access(p.250)
- • Strong financial performance with highest OPBDIT margin among peers(p.239)
- • Ability to attract and retain high-caliber medical professionals with international training(p.245)
- • Strong track record of disciplined growth and profitability(p.251)
- • Institutional shareholder support and governance framework(p.252)
- • Established multi-specialty healthcare network across multiple geographies(p.299)
- • Long operational history and brand recognition in pediatrics and women's healthcare(p.299)
- • Strong promoter backing and institutional investor involvement(p.301)
- • Multiple accreditations demonstrating quality and safety standards(p.302)
- • Recognition as a great place to work(p.302)
- • Multi-hospital network with consolidated operations across multiple facilities(p.370)
- • Significant profit growth and operational leverage in nine-month period(p.365)
- • Strong cash generation from operations(p.366)
- • Diversified revenue streams from hospital services, pharmacy, and medical fees(p.411)
- • Leading multi-specialty pediatric and obstetrics network with largest bed capacity among comparable players(p.443)
- • Established brand reputation and 22-year operational history in pediatric specialty care(p.444)
- • High full-time doctor retention rate and exclusive engagement model ensuring 24/7 specialist availability(p.444)
- • International clinical expertise with doctors trained in UK, US, Canada and Australia(p.444)
- • Hospital accreditations and certifications demonstrating quality standards(p.444)
- • Financially disciplined capital expenditure approach enabling profitable growth(p.444)
- • Proven hub-and-spoke model generating market synergies and referrals(p.444)
- • Strong patient volume growth and operational recovery post-COVID(p.464)
- • Reputation and specialization in high-risk obstetrics driving higher ARPU(p.464)
- • Strong cash generation from operations(p.470)
- • Established hospital network in key cities with maturity benefits(p.468)
- • Investor director representation and governance protections(p.597)
- • Comprehensive information rights and transparency requirements(p.598)
- • Anti-dilution protection for investors(p.607)
- • Liquidation preference protection(p.616)
- • Reserved matters consent mechanism protecting investor control(p.601)
- • Clear exit rights framework with IPO as primary goal(p.612)
- • Drag-along and tag-along rights for investor protection(p.615)
Weaknesses
- • High dependency on medical professionals with significant doctor attrition risk(p.53)
- • Concentration of patient volumes in two geographic locations(p.55)
- • Dependence on consultancy-based doctor arrangements with no employment guarantees(p.55)
- • Outstanding litigation including drug storage complaints against the company(p.62)
- • High debt redemption obligation using IPO proceeds(p.56)
- • High dependence on few major suppliers for medical consumables(p.70)
- • Bed occupancy rates declined significantly during COVID-19 despite capacity expansion(p.65)
- • Litigation involving promoters and directors at various adjudication levels(p.73)
- • Moderate indebtedness with restrictive covenants limiting strategic flexibility(p.69)
- • Heavy reliance on third-party service providers without direct control(p.71)
- • High promotional shareholding concentration(p.139)
- • Limited geographic presence outside South India and NCR(p.209)
- • Debt obligations to group company requiring early redemption(p.161)
- • Heavy reliance on major institutional investor CDC(p.134)
- • Proposed capital-intensive expansion requiring ₹1,700 million in equipment and new hospital setup(p.160)
- • High occupancy rate volatility and dependence on specific geographies(p.246)
- • Concentration of mature hospital operations in Hyderabad cluster(p.234)
- • New hospitals require significant cash investment with initial operating losses(p.251)
- • High dependence on full-time doctor retention and recruitment challenges(p.250)
- • Significant capital expenditure requirements for expansion(p.245)
- • Dependence on key medical professionals for service delivery(p.341)
- • Project execution delays and cost overruns in expansion(p.303)
- • Concentration of operations in specific geographic locations(p.301)
- • High lease liability burden relative to total assets(p.364)
- • Significant long-term borrowings outstanding(p.408)
- • Property title not held in company name for key asset(p.396)
- • Substantial contingent tax liabilities across multiple jurisdictions(p.393)
- • Vulnerability to high professional service costs(p.412)
- • High concentration of lease liabilities creating long-term financial obligations(p.426)
- • Significant dependence on medical consumables and pharmacy procurement with top five suppliers representing 54.45% of purchases(p.450)
- • Material contingent liabilities from tax disputes and claims not acknowledged as debt(p.414)
- • Company Secretary position was vacant from April 1, 2021 to August 31, 2021(p.432)
- • Deferred tax asset recognition on unabsorbed depreciation uncertain due to uncertain future profitability(p.414)
- • Heavy dependence on Hyderabad and Bengaluru hospitals for revenue(p.474)
- • Material contingent liabilities and tax demands under dispute(p.473)
- • Significant ongoing consumer litigation and medical negligence claims(p.479)
- • High finance costs and lease liabilities burden(p.465)
- • Dependency on certain medical specialties for majority of revenues(p.474)
- • Investor control termination upon shareholding dilution(p.620)
- • Dependence on promoter consent for various material actions(p.612)
- • Promoter majority on board with limited investor representation(p.597)
- • Promoter control over key personnel compensation(p.609)
Opportunities
- • Growing pediatric and maternity healthcare market with strong projected CAGR(p.25)
- • Planned expansion into new geographic markets through new hospital setup(p.26)
- • Expansion of hub-and-spoke model to broaden service delivery(p.59)
- • Expansion of hub-and-spoke model to new locations (Delhi, Chennai)(p.64)
- • Increasing health insurance penetration in India creating addressable market(p.77)
- • Capital deployment for new hospital infrastructure via IPO proceeds(p.97)
- • Significant growth in pediatric market expected at 13% CAGR through FY26(p.217)
- • Rising maternity care market growing at 8-12% CAGR in private sector(p.211)
- • Expansion into Tier II and III cities through hub-and-spoke model(p.209)
- • Demographic growth with 240 million females in reproductive age and young population(p.190)
- • Rising household incomes increasing affordability of quality healthcare(p.207)
- • Government focus on healthcare through PMJAY and policy support(p.203)
- • Pediatric healthcare market expected to grow at 13% CAGR through FY26(p.249)
- • Maternity healthcare market expected to grow at 9.42% CAGR through FY26(p.250)
- • Private NICU market expected to grow at 15% CAGR through FY26(p.220)
- • Private maternity care market expected to grow at 11-12% CAGR through FY26(p.229)
- • Rising maternal age and pregnancy complications driving demand for specialized care(p.222)
- • Increasing institutional delivery preference and private hospital demand in urban areas(p.226)
- • Growing health insurance penetration and government healthcare schemes(p.222)
- • Expansion opportunity through hub-and-spoke model replication across new cities(p.254)
- • Expansion into new geographies and service offerings across India(p.299)
- • Growth in emerging health schemes and government healthcare coverage(p.289)
- • Telemedicine adoption and digital healthcare expansion(p.289)
- • Development of specialty centers and IVF/fertility services(p.301)
- • UP to 100% FDI permitted in healthcare sector(p.298)
- • Significant capital investment in healthcare infrastructure expansion(p.395)
- • Planned commissioning of new hospital facility at Vishakhapatnam(p.396)
- • Growing equity capital base enabling financing flexibility(p.369)
- • Conversion of preference shares to equity providing capital structure flexibility(p.404)
- • Hub-and-spoke model expansion to new cities including Chennai and New Delhi-NCR(p.448)
- • Growth through brownfield and greenfield hospital acquisition and development(p.444)
- • Digital healthcare ecosystem expansion to increase patient reach(p.444)
- • Recovery and growth from COVID-19 pandemic normalization with improved patient volumes(p.445)
- • Revenue growth from COVID-19 vaccination programs at hospitals(p.445)
- • Expansion with two new operational hospitals increasing capacity(p.467)
- • Growing demand for high-risk pregnancy and pediatric services post-COVID(p.464)
- • Increased secondary care pediatrics demand(p.464)
- • Pharmacy services revenue growth potential(p.465)
- • IPO pathway with investor share sale priority(p.612)
- • Investor stake sale freedom post-2021(p.606)
- • Buyback exit option available to investors(p.614)
- • Multiple exit scenarios available by 2023(p.612)
Threats
- • COVID-19 pandemic impact on patient volumes and occupancy rates(p.57)
- • Intense competition from public hospitals, private hospitals and new market entrants(p.63)
- • Regulatory compliance requirements and potential government price controls(p.61)
- • Pharmaceutical price control regulations limiting revenue on drug sales(p.62)
- • Regulatory changes in assisted reproductive technology sector(p.61)
- • Potential shortage of qualified medical professionals in Indian healthcare sector(p.54)
- • Intense competition from government hospitals, private hospitals, and non-profit organizations(p.66)
- • Government price control measures limiting pricing power(p.66)
- • Seasonality reducing patient visits during March-May examination/vacation periods(p.77)
- • Rising input costs (medical consumables, pharmaceuticals) may not be passable to patients(p.74)
- • Regulatory risks from evolving healthcare and data protection laws(p.72)
- • Economic slowdown and inflation reducing patient disposable income for healthcare(p.67)
- • COVID-19 and other pandemics causing unpredictable operational disruptions(p.67)
- • High neonatal mortality rates and unmet pediatric healthcare demand remains persistent(p.219)
- • Intense competition from established multi-specialty hospital chains(p.208)
- • COVID-19 pandemic impact on pediatric healthcare facilities(p.217)
- • Regulatory requirements for hospital operations and staffing(p.201)
- • High capital requirements and potential shortage of specialized talent(p.209)
- • India's low healthcare spending and out-of-pocket expenditure dependency(p.194)
- • Competition from established multi-specialty hospital chains with broader service offerings(p.280)
- • Regulatory uncertainty and evolving healthcare regulations(p.284)
- • Pediatric healthcare market faces challenges in sourcing and retaining quality doctors(p.250)
- • Dependence on leasehold properties with renewal risks(p.282)
- • Vulnerability to economic cycles and consumer affordability changes(p.221)
- • Stringent regulatory requirements for healthcare operations and licensing(p.288)
- • Complex compliance requirements across multiple healthcare legislations(p.291)
- • Price regulation of essential medicines and drugs(p.290)
- • Mandatory waste management and biomedical waste handling requirements(p.292)
- • Restrictive FPI investment caps limiting foreign investor participation(p.298)
- • Dependency on limited property assets with title held by government entity(p.396)
- • Reliance on subletting arrangements subject to regulatory restriction(p.396)
- • Exposure to multiple tax disputes across jurisdictions(p.393)
- • High finance costs from lease liabilities creating fixed obligations(p.411)
- • Increasing allowances for expected credit losses on receivables(p.412)
- • Occupancy rates significantly impacted by COVID-19 lockdowns and movement restrictions(p.445)
- • Volatility in medical consumables and pharmaceutical costs from market demand and government pricing policies(p.450)
- • Extensive regulatory requirements and need for multiple governmental approvals across multiple jurisdictions(p.450)
- • Patient volumes dependent on economic conditions, seasonal illness cycles and competitive landscape(p.445)
- • Significant uncertainty regarding Code on Social Security, 2020 implementation impact on employee contributions(p.432)
- • Seasonality affecting patient visits during specific periods(p.474)
- • Regulatory risks related to drugs and medical compliance(p.479)
- • Interest rate risk on floating rate borrowings(p.474)
- • Foreign exchange exposure from medical imports(p.474)
- • ESG breach risk with material remediation requirements(p.619)
- • Regulatory restrictions on promoter share transfers(p.608)
- • Insolvency or financial distress of promoter triggers default(p.618)
- • Risk of gross mismanagement by promoters(p.618)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Ramesh Kancharla | Promoter | 38.25% | 31.03% |
| Dr. Dinesh Kumar Chirla | Promoter | 8.89% | 6.53% |
| Dr. Adarsh Kancharla | Promoter | 7.84% | 6.02% |
| Dr. Ramesh Kancharla | Promoter | 23.12% | 18.62% |
| Dr. Dinesh Kumar Chirla | Promoter | 8.32% | 6.71% |
| Dr. Adarsh Kancharla | Promoter | 6.25% | 5.05% |
| British International Investment plc (formerly known as CDC Group plc) | Investor Selling Shareholder | 5.00% | — |
| CDC India | Investor Selling Shareholder | 5.21% | — |
| Padma Kancharla | Other Selling Shareholder | 0.63% | — |
| Dr. Ramesh Kancharla | Promoter | 38.25% | 36.30% |
| British International Investment plc (formerly known as CDC Group plc) | Investor Selling Shareholder | 20.00% | — |
| CDC India | Investor Selling Shareholder | 10.45% | — |
| Dr. Dinesh Kumar Chirla | Promoter | 8.89% | 8.43% |
| Dr. Adarsh Kancharla | Promoter | 7.84% | 7.44% |
| Kancharla Family Trust | Promoter Group | 5.38% | 5.10% |
| Sai Geeta Dinesh Trust | Promoter Group | 1.08% | 1.02% |
| Dr. Poddutoor Preetham Kumar | Shareholder (1%+) | 1.25% | — |
| Dr. Ramesh Kancharla | Founding Promoter | — | — |
| CDC (UK's development finance institution) | Financial Investor | — | 30.45% |
| Dr. Dinesh Kumar Chirla | Promoter | — | — |
| Dr. Ramesh Kancharla | Promoter | 38.25% | — |
| Dr. Dinesh Kumar Chirla | Promoter | 8.89% | — |
| Dr. Adarsh Kancharla | Promoter | 7.84% | — |
| Dr. Ramesh Kancharla | Promoter | 45.53% | 39.18% |
| Dr. Dinesh Kumar Chirla | Promoter | 10.92% | 9.10% |
| Dr. Adarsh Kancharla | Promoter | 5.26% | 8.03% |
| British International Investment plc (formerly known as CDC Group plc) | Promoter Group | 19.30% | 19.26% |
| CDC India Opportunities Limited | Promoter Group | 8.87% | 9.50% |
| Kancharla Family Trust | Promoter Group | — | 5.51% |
| Dr. Ramesh Kancharla | Promoter/Chairman and Managing Director | — | — |
| Dr. Dinesh Kumar Chirla | Promoter/Whole-time Director | — | — |
| Dr. Adarsh Kancharla | Promoter | — | — |
| British International Investment plc (formerly known as CDC Group plc) | Investor Selling Shareholder | — | — |
| CDC India | Investor Selling Shareholder | — | — |
| Padma Kancharla | Other Selling Shareholder | — | — |
| Dr. Ramesh Kancharla | Promoter No. 1 | — | — |
| Padma Kancharla | Other Shareholder | — | — |
| Dinesh Kumar Chirla | Promoter | — | — |
| Dr. Ramesh Kancharla | Promoter/Chairman and Managing Director | — | — |
| Dr. Dinesh Kumar Chirla | Promoter/Whole-time Director | — | — |
| Dr. Adarsh Kancharla | Promoter | — | — |
| Padma Kancharla | Other Shareholder | — | — |
Leadership
Dr. Ramesh Kancharla · Chairman and Managing Director
Dr. Dinesh Kumar Chirla · Whole-time Director
R Gowrisankar · Chief Financial Officer
Ashish Kapil · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Rainbow Childrens Medicare IPO FAQs
What is the lot size of Rainbow Childrens Medicare IPO?
The minimum lot size of Rainbow Childrens Medicare IPO is 27 shares. One lot costs ₹14,634 at the cut-off price.
When does Rainbow Childrens Medicare IPO open and close?
Rainbow Childrens Medicare IPO opened for subscription on 27 Apr 2022 and closed on 29 Apr 2022.
What is the listing date of Rainbow Childrens Medicare IPO?
Rainbow Childrens Medicare IPO listed on 10 May 2022.